NasdaqGS:IMVTBiotechs
How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones
Immunovant, Inc. recently reported Q3 2025 results with a smaller-than-expected quarterly loss and updated timelines for key autoimmune clinical programs, including proof-of-concept studies in cutaneous lupus erythematosus and rheumatoid arthritis, plus Phase 3 trials of batoclimab in thyroid eye disease, all expected to read out in 2026.
An interesting angle is how Immunovant’s growing autoimmune antibody pipeline, backed by parent Roivant Sciences Ltd., is increasingly central to the...